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ABSTRACT
The epigenetic mechanisms underlying chemoresistance in cancer cells resulting from drug-induced
reversible senescence are poorly understood. Chemoresistant ESC-like embryonal carcinoma PA1 cells
treated with etoposide (ETO) were previously found to undergo prolonged G2 arrest with transient p53-
dependent upregulation of opposing fate regulators, p21CIP1 (senescence) and OCT4A (self-renewal).
Here we report on the analysis of the DNA methylation state of the distal enhancer (DE) and proximal
enhancer (PE) of the Oct4A gene during this dual response. When compared to non–treated controls the
methylation level increased from 1.3% to 12.5% and from 3% to 19.4%, in the DE and PE respectively. It
included CpG and non-CpG methylation, which was not chaotic but presented two patterns in each
enhancer. Discorrelating with methylation of enhancers, the transcription of Oct4A increased, however, a
strong expression of the splicing form Oct4B was also induced, along with down-regulation of the Oct4A
partners of in the pluripotency/self-renewal network Sox2 and Lin28. WB demonstrated disjoining of the
OCT4A protein from the chromatin-bound fraction. In survival clones, methylation of the DE was
considerably erased, while some remnant of methylation of the PE was still observed. The alternative
splicing for Oct4B was reduced, Oct4A level insignificantly decreased, while the expression of Sox2 and
Lin28 recovered, all three became proportionally above the control. These findings indicate the
involvement of the transient patterned methylation of the Oct4A enhancers and alternative splicing in the
adaptive regulation of cell fate choice during the p53-dependant dual state of reversible senescence in
ESC-like cancer stem cells.
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The model of the drug-induced reversible senescence of
germ cancer stem cells reveals an unusual behaviour of
Pou5f1 (Oct4A) gene
Resistance of cancer stem cells (CSC) to genotoxic modalities is
the main cause of disease relapse and mortality of cancer
patients. In the last period this response is associated with
induction of reversible stress-induced cell senescence of CSC,
whose mechanisms and prediction of the outcome are far from
understood [1]. As a model to study this phenomenon, we
chose the ovarian embryonal carcinoma cell line PA1 (wt
TP53), treated with etoposide (ETO), the inhibitor of Topo-
isomerase II. Embryonal carcinomas such as PA1 possess the
features of, and are often used as, an analog for embryonal
stem cells (ESC) [2]. Using this model we previously found that
ETO treated PA1 cells entered massive G2-arrest, assumed flat
morphology, and signalled the DNA damage response (DDR)
for about 4–5 days in approximately 100% of cells (with cell
nuclei marked by ϫH2AX and CHK2 foci), indicating cell
senescence [3,4]. However the normal cell cycle did recover
through clones escaping senescence. The most surprising fact
was the finding of heterogeneous activation of opposite regula-
tors of senescence (p21CIP1) and the core regulator of self-
renewal/pluripotency (OCT4A) in these enlarged, flattened
cells. This paradoxical duality for senescence and self-renewal
was shown to be p53 dependent, as both p21CIP1 and OCT4A
became down-regulated by siRNA p53 [4]. In turn OCT4A
moderated the expression of p21CIP1. The re-growth of sur-
vival clones starting from day 7–10 was abolished by OCT4
mRNA silencing [3]. Interestingly, the stress-activated OCT4A
protein accumulated in cell the nuclei but was mostly disjoined
from binding to the chromatin fraction; in addition the alterna-
tive splicing of its gene was determined by RT-PCR [4].
Aim of the current study
The unusual expression and behavior of Oct4A (POU5F1) gene
and protein in this model of reversible senescence prompted us
to explore the methylation state of the Oct4A gene regulatory
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elements. In this study, the DNA methylation analysis of two
regulatory enhancers, proximal (PE) and distal (DE) in control
and ETO-treated cells, on day 3 and day 20 (post-recovery) was
carried out. To verify previous findings of Oct4 expression, RT-
qPCR analysis of Oct4A and Oct4B expression was undertaken
as well as analysis of additional components of the self-
renewal/pluripotency network Sox2 and Lin28 [5–7].
Results
The real-time PCR reveals up-regulation of Oct4A and
Oct4B and down-regulation of Sox2 and Lin28 in
Etoposide–treated cells, reversed in survival clones
Expression of Oct4A, Oct4B, Sox2 and Lin28 in control, 3 days
and 20 days post ETO treatment was measured by RT-qPCR
(Fig. 1). This analysis confirmed the previous results of semi-
quantitative-PCR [4] of the expression profile change with
induction of both enhanced OCT4A transcription but even
more spectacular induction of its alternative splicing Oct4B
transcript. Moreover, a several-fold decrease of expression of
the direct and indirect partners of Oct4A in the pluripotency
network, Sox2 and Lin28 after ETO were observed on day 3
(Fig. 1). The reduction of Sox2 and Lin28 when considered
with the disjoining of Oct4A from the chromatin binding [4]
indicates a loss of the pluripotency function of OCT4A. How-
ever, in the surviving clones on day 20 the transcription levels
of Oct4A insignificantly decreased, while the amounts of its
partners in the pluripotency network increased, all three
becoming proportionally above the control levels (Fig. 1) indi-
cating to restoration of the pluripotency and self-renewal
enhancement.
ETO induces moderate DNA methylation of distal enhancer
(DE) and proximal enhancer (PE) of Oct4A gene, reversed
in survival clones
DNA methylation of the Oct4A regulatory upstream elements
was also examined in non-treated (NT) PA1 cells, 3 days post
ETO treatment, during prolonged G2 arrest, and on day 20
post ETO treatment (Fig. 2). In the NT control, the enhancers
were practically un-methylated. The moderate methylation of
Oct4A enhancers, including CpG and non-CpG sites was
observed on day 3 post ETO, increasing in DE from 1.3% to
12.5% and in PE from 3% to 19.4%. The methylation was not
chaotically spread but targeted to specific locations. In particu-
lar, two distinctive methylation patterns were seen in each
enhancer (marked on Fig. 2). Besides, we found some clones
presenting CCWGG methylation in DE (Figs. 2 b and 3) with-
out methylated CpGs. DE the CpG methylation in the proxim-
ity of the SOX2-OCT4 heterodimer binding site and
methylation in the CCWGG epigenetic mark in the vicinity of
the NANOG p1 binding sequence is observed (Supplemental
Fig. 1). It is interesting to note that PE contains a cluster of 8
Figure 1. RT-qPCR shows that treatment of PA-1 cells with etoposide (ETO) leads
on day 3 to bias of enhanced expression of the conventional and alternative splic-
ing of POU5F1/Oct4 which is coupled to downregulation of the Oct4A partners in
the pluripotency network Sox2 and Lin28. The discorrelation between the Oct4A,
Sox2 and Lin28 is corrected, while the splicing variant Oct4B drops down, in the
survival cells on day 20. Average numbers from two independent experiments are
presented. Relative mRNA levels are shown after normalization against four house-
keeping genes for every sample (for details see Material and Methods). mRNA lev-
els in non-treated (NT) cells are arbitrary set as 1 and shown as folds after ETO
treatment. Statistical significance is shown by a two-tailed T-test:p<0.05;
p<0.01.
Figure 2. The results of bisulphite sequencing analysis of proximal and distal
enhancers of Oct4A promoter regions. Each row of circles for a given amplicon rep-
resents the methylation status of CpGs or CCWGGs nucleotides (correspondingly,
circles and squares) in one clone for that region. Number of columns corresponds
to the number of analysed clones (16). Open circles and squares are un-methylated
CpGs and CCWGGs, while the closed ones are methylated. (a) and (c) represent the
two presumably distinctive methylation patterns of DE; (b) the two clones where
only CCWGG methylation was detected; (d) and (e) correspond to two presumably
distinctive methylation patterns of PE.
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CCWGG (W = A/T) motifs with 6 of them corresponding to
CCAGGs which represent targets for 5’-CAG-3’ methylation
which predominantly occurs in ESC and oocytes [8,9]. In the
PE, we observed a more pronounced methylation of CCWGG
motifs as compared with DE. The pattern of the CpG and non-
CpG methylation induced by ETO in the PE partially resem-
bled much heavier methylated PE of differentiated peripheral
blood leukocytes (Fig. 2). On day 20, in recovery clones we
found methylation of DE and PE had been profoundly, but not
fully, reduced and of the two distinctive methylation patterns
were not observed anymore (Fig. 2). The observed residual
CpG and CCWGG methylation in regulatory enhancers might
reflect heterogeneity of recovering clonal population of PA1
cells (remnant senescent cells) as well as the drift of PE methyl-
ation in some clones.
Discussion
The altered expression profile of the Oct4A gene induced by
ETO is accompanied by an induction in alternative splicing
forms Oct4B and Oct4B1, in addition Oct4-PG1 was also
induced, all together more closely resembling the expression
pattern seen in terminally differentiated peripheral blood leu-
kocytes (PBL) [4]. Interestingly, the pattern of the enhanced
methylation of the DE and particularly PE of Oct4A gene also
tended towards the pattern of more heavily methylated PBL as
seen on Fig. 2. This suggests the epigenetic state of PA1-ETO
senescent cells is prepared for a shift in the fate commitment
from pluripotency to differentiation. However, this state is
unstable: when cells recovered clonogenic growth, the moderate
methylation of enhancers became mostly erased, alternative
splicing transcription of Oct4 gene went down, while the tran-
scription of Oct4A partners in the self-renewal and pluripo-
tency network Sox2 and Lin28 was recovered and even
enhanced.
This interesting situation should be discussed in frames of
the response of ESC-like germ cancer wt TP53 cells to geno-
toxic damage, which our PA1-ETO model represents. Firstly,
ESC cells are known as not possessing the G1/S checkpoint and
therefore are arrested after DNA damage directly in the G2/M
damage checkpoint [10]. Secondly, in this checkpoint, the
phosphorylation within the homeobox region of OCT4 by
Aurora B kinase (AURKB) was shown negatively regulating its
activity by interrupting sequence-specific DNA binding
[11,12]. In accord with this data, we see in our model that
inspite of the wt TP53 (which should arrest the DNA damaged
somatic cells in G1), the PA1-ETO cells entirely entered the
G2/M arrest, were positive there for AURKB (not shown), and
disjoined OCT4A from the chromatin [4]. Thus the interrup-
tion of the positive feed-back loop of Oct4A itself and of its
partners in the core self-renewal network has occurred.
How these obstacles may be related to transient moderate
methylation of Oct4A enhancers in the drug-induced reversible
cell senescence?
The methylation of Oct4 regulatory elements inducing alter-
native splicing of the Oct4B form has been previously reported
[13]. As well, the recently revealed suppressive function of
Oct4B by its non-coding RNA on translation of Oct4A may be
mentioned [14], However, these data mostly refer to somatic
tumors; in addition, DNA methylation of enhancers is regu-
lated in cell-type specific manner [15]. Here, in the germ
(oocyte) cancer cell model after ETO, along with some degree
of enhancer methylation and shift to Oct4B alternative splicing,
the surprising induction of enhanced transcription and accu-
mulation of the OCT4A protein itself needs explanation, or at
least a working hypothesis. Gene expression suppression by
CpG methylation is well established [16,17] but as to non-CpG
methylation found in our model, the situation is not unequivo-
cal [18]. The finding of presumably two patterns of the methyl-
ation in two enhancers including both CpG and non-CpG
sequences suggests a possibility of the operational switch of
promoters for Oct4A to its splicing forms in the dual stage of
senescence and self-renewal.We hypothesize that both Oct4A
and Oct4B forms can be transcribed by shifts from one methyl-
ation pattern of Oct4 enhancers to another (may be, through a
metastable CCWGG bridge) supporting the metastability of
reversible senescence. We cannot exclude that two different
Oct4A methylation patterns belong to different cells in the pop-
ulation, heterogenous for the OCT4/p21CIP1 expression ratio
or even to two different epigenomes in the same G2-arrested
cell.
Preference of this checkpoint, with the doubled DNA con-
tent, for arrest may be a prerequisite of cell fate divergence by
bi-polarity of two epigenomes and sorting DNA damage/senes-
cence from self-renewal in an asymmetric/symmetric two-step
division noticed in this and similar models [19]. We also sug-
gest that although transiently non-functional in the pluripo-
tency network, the accumulated long-lived OCT4A protein, in
addition to its p21CIP1 moderating function [3], retains an
option to be operatively involved in the pluripotency network
by an autocatalytic loop of its own and then attract the tran-
scription of its network partners [5,20]. This could occur as
soon as the DNA damage is repaired or sorted, the cell resumes
division and enters G1, and the mechanism of keeping stressed
OCT4A away from the chromatin binding (in G2 arrest) is
withdrawn together with TP53 activation. It should be noted in
addition, that activated p53 directly suppresses the promoter of
the gateway to the pluripotent state, Nanog [21–23] whose tran-
scription is however fluctuating [24,25]. Both p53-dependent
mechanisms thus provide an option for a bi-stable switch
between self-renewal/pluripotency and senescence/differentia-
tion allowing the adaptive choice of individual cell fates.
In conclusion, we revealed in wtTP53 PA1-ETO cells the
DDR response by the moderate two-patterned methylation of
Figure 3. Fragment of sequencing chromatogram of bisulphite treated DNA dem-
onstrating the presence of CCWGG methylation.
364 M. BARYSHEV ET AL.
the distal and proximal Oct4A enhancers activates both con-
ventional and alternative splicing forms of Oct4A transcripts,
characterizing the reversible cell senescence of these ESC-like
embryonal carcinoma cells.
Material and methods
Cell treatment, DNA extraction and bisulfite analysis
The treatment with ETO of PA1 cells was performed in the
experiments reported earlier [1,2]. In brief, cells were treated
with 8mM ETO for 20 h and afterwards cultivated and fed in
normal medium without antibiotics. After discarding the
medium with floating dead cells the PA1cells were detached
from support and collected by centrifugation. Genomic DNA
of ETO-treated and non-treated PA1 cells was obtained by
overnight cell incubation in TES buffer containing 0.1% SDS
and 100 mg/ml proteinase K at 55 C with subsequent phenol/
chloroform extraction and isopropanol precipitation. 2 mg of
DNA in 50 ml of TE buffer was denatured during15 minutes in
0.3 M NaOH at 37C. The denatured DNA was mixed with
550 ml of freshly prepared solution of 10 mM hydroquinone
and 3 M sodium bisulfite at pH 5.0, and incubated under min-
eral oil at 50 C for 12 h. Bisulfite treated DNA was desalted by
isopropanol precipitation, desulfonated with 0.3 M NaOH for
5 min at room temperature, and precipitated with ethanol.
Converted DNA was dissolved in 100 ml of water and stored at
-20C. 3 ml of precipitated DNA were used for each PCR. DNA
of peripheral white blood cells (WBC) was used as a control for
normal differentiated quiescent cells.
Bisulfite sequencing analysis
The bisulfite treated DNA was used to amplify the proximal
and distal enhancers (PE, DE) of OCT4 promoter region
with primers specific for bisulfite converted DNA: DE of
OCT4, forward: 5'-AGGAGTTATTAGGAAAATGGGTAG-
TAG-3', reverse: 5'-TACCTTCTAAAAAAATAAATATCCC-
3'. For PE of OCT4, forward: 5’-GGG GAG TTT AGG GTA
GTT TTT TTG-3’, reverse: 5'-AAA CTA ACT AAA CCT CAA
TTT CCC AA-3'. The PCR reaction was carried out using 2.5
units of homemade Taq polymerase in a final volume of 50 ml
and the following cycling conditions: 5 minutes at 95 C, fol-
lowed by 35 cycles (30 seconds denaturation at 95 C, anneal-
ing for 30 seconds at 62 C and elongation at 72 C for 1
minute. The PCR products were gel purified and cloned using
TOPO TA cloning kit. To prevent clonal amplification of
sequences, the competent cells transformed were plated
immediately after heat shock; excluding shaking bacteria for
1 h. 16 clones for each PCR product were sequenced and ana-
lysed. The methylation analysis of enhancers was performed by
alignment of sequenced clones against the genomic region cor-
responding to appropriate enhancer. The efficiency of cytosine
to uracil conversion was estimated as the ratio of cytosine in a
non-CpG context to total number of cytosine in the region.
The clones with the efficiency of cytosine conversion less than
98% were omitted from the analysis.
DNA sequencing was performed using the ABI BigDyeTer-
minator Cycle Sequencing Kit v3.1 according to the manufac-
turer’s instructions on a Gene Amp 9700 PCR machine and the
sequences were detected on an ABI 3130XLGenetic Analyzer.
Real-time RT-PCR
Total RNA was extracted from PA-1 cells (2 £ 106 cells) by
using TRIZOL (Invitrogen). First-strand cDNA was synthe-
sized using 2,5 mg of RNA, random hexamers and RevertAidTM
M-MuLV Reverse Transcriptase (Fermentas, Lithuania)
according to the manufacturer’s protocols, and subsequently
diluted with nuclease-free water (Fermentas) ten times. Real-
time PCR was run on a ViiA7 (Applied Biosystems). Amplifica-
tion mixtures (25 ml) contained 2ml template cDNA, 2xSYBR
Green Master Mix buffer (12,5 ml) (Life Technologies, Carls-
bad, CA, USA) and 2mM forward and reverse primer (Table 1).
The cycling conditions comprised 10 min polymerase activa-
tion at 95oC and 40 cycles at 95oC for 15 sec and 60oC for
60 sec. A melt curve was also performed after the assay to check
for specificity of the reaction. This consistent of 20 sec at 72o C
followed by a ramp up of 1o step with 5-sec hold at each step.
Every cDNA sample was normalized against four housekeeping
genes: GAPDH, ACTB, B2M, and LRP10 using giNorm soft-
ware [26]. The calculated gene expression stability coefficient
M was applied to Q-PCR results.
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Table 1. Forward and reverse primer sequences used in real-time RT-PCR
Gene Forward primer sequence Reverse primer sequence Reference
Oct4A TCGCAAGCCCTCATTTCACC GCCAGGTCCGAGGATCAAC [27]
Oct4B AGACTATTCCTTGGGGCCACAC GGCTGAATACCTTCCCAAATAGA [27]
Sox2 GTACTGGCGAACCATCTCTGTG CCAACGGTGTCAACCTGCATG
Lin28 CGGGCATCTGTAAGTGGTTC CAGACCCTTGGCTGACTTCT [28]
GAPDH GGGTCTTACTCCTTGGAGGC GTCATCCCTGAGCTAGACGG [26]
ACTB AATCTCATCTTGTTTTCTGCGC AGTGTGACGTGGACATCCG [26]
B2M TCTCGCTCCGTGGCCTTAGC GCCTACCTACTTTGGGTCTGTGT [26]
LRP10 ACCGCTGCAACTACCAGACT ACGTCGACATTACTGGAAC [26]
CELL CYCLE 365
Funding
The study was supported by the Europe Social Fund Project, project No.
2013/0023/1DP/1.1.1.2.0/13/APIA/VIAA/037. The publishing costs are
covered by the Riga Stradins University.
ORCID
Anda Huna http://orcid.org/0000-0003-2030-8865
Thomas R Jackson http://orcid.org/0000-0003-3214-3973
Jekaterina Erenpreisa http://orcid.org/0000-0002-2870-7775
References
[1] Erenpreisa J, Salmina K, Cragg MS. Accelerated senescence of cancer
stem cells: a failure to thrive or a route to survival? In: Dorszewska J,
ed. Senescence – Physiology or Pathology. InTech; 2017. doi:10.5772/
intechopen.68582.
[2] Andrews PW, Matin MM, Bahrami AR, et al. Embryonic stem (ES)
cells and embryonal carcinoma (EC) cells: opposite sides of the same
coin. Biochem Soc Trans. 2005;33(6):1526. doi:10.1042/
BST20051526. PMID:16246161
[3] Huna A, Salmina K, Erenpreisa J, et al. Role of stress-activated
OCT4A in the cell fate decisions of embryonal carcinoma cells
treated with etoposide. Cell Cycle. 2015;14(18):2969–2984.
doi:10.1080/15384101.2015.1056948. PMID:26102294
[4] Jackson TR, Salmina K, Huna A, et al. DNA damage causes TP53-
dependent coupling of self-renewal and senescence pathways in
embryonal carcinoma cells. Cell Cycle. 2013;12(3):430–441.
doi:10.4161/cc.23285. PMID:23287532
[5] Boyer LA, Lee TI, Cole MF, et al. Core Transcriptional Regulatory
Circuitry in Human Embryonic Stem Cells. Cell. 2005;122(6):947–
956. doi:10.1016/j.cell.2005.08.020.
[6] Rizzino A. Sox2 and Oct-3/4: a versatile pair of master regulators that
orchestrate the self-renewal and pluripotency of embryonic stem
cells. Wiley Interdiscip Rev Syst Biol Med. 2009;1(2):228–236.
doi:10.1002/wsbm.12. PMID:20016762
[7] Darr H, Benvenisty N. Genetic analysis of the role of the reprogram-
ming gene LIN-28 in human embryonic stem cells. Stem Cells.
2009;27(2):352–362. doi:10.1634/stemcells.2008-0720. PMID:19038789
[8] Laurent L, Wong E, Li G, et al. Dynamic changes in the human
methylome during differentiation. Genome Res. 2010;20(3):320–331.
doi:10.1101/gr.101907.109. PMID:20133333
[9] Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at
base resolution show widespread epigenomic differences. Nature.
2009;462(7271):315–322. doi:10.1038/nature08514. PMID:19829295
[10] Neganova I, Lako M. G1 to S phase cell cycle transition in somatic
and embryonic stem cells. J Anat. 2008;213(1):30–44. doi:10.1111/
j.1469-7580.2008.00931.x. PMID:18638068
[11] Brumbaugh J, Hou Z, Russell JD, et al. Phosphorylation regulates
human OCT4. Proc Natl Acad Sci. 2012;109(19):7162–7168.
doi:10.1073/pnas.1203874109. PMID:22474382
[12] Shin J, Kim TW, Kim H, et al. Aurkb/PP1-mediated resetting of Oct4
during the cell cycle determines the identity of embryonic stem cells.
Elife. 2016;5:e10877. doi:10.7554/eLife.10877. PMID:26880562
[13] Wang Y, Meng L, Hu H, et al. Oct-4B isoform is differentially
expressed in breast cancer cells: hypermethylation of regulatory ele-
ments of Oct-4A suggests an alternative promoter and transcrip-
tional start site for Oct-4B transcription. Biosci Rep. 2011;31:109–
115. doi:10.1042/BSR20100033. PMID:20433421
[14] Li D, Yang Z-K, Bu J-Y, et al. OCT4B modulates OCT4A expression
as ceRNA in tumor cells. Oncol Rep. 2015;33(5):2622–2630.
doi:10.3892/or.2015.3862. PMID:25812694
[15] Choi HW, Joo JY, Hong YJ, et al. Distinct Enhancer Activity of Oct4
in Naive and Primed Mouse Pluripotency. Stem Cell Reports. 2016;7
(5):911–926. doi:10.1016/j.stemcr.2016.09.012. PMID:28157483
[16] Bird AP. CpG-rich islands and the function of DNAmethylation. Nature.
1986;321(6067):209–213. doi:10.1038/321209a0. PMID:2423876
[17] Robertson KD, Jones PA. DNA methylation: past, present and future
directions. Carcinogenesis. 2000;21(3):461–467. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/10688866. Accessed Decem-
ber 5, 2017. doi:10.1093/carcin/21.3.461. PMID:10688866
[18] Jin J, Lian T, Gu C, et al. The effects of cytosine methylation on gen-
eral transcription factors. Sci Rep. 2016;6(1):29119. doi:10.1038/
srep29119. PMID:27385050
[19] Erenpreisa J, Salmina K, Belyayev A, et al. Survival at the brink:
chromatin autophagy of tumour cells in response to genotoxic
damage. In: Hayatt MA, ed. Autophagy: cancer, other patholo-
gies, inflammation, immunity, infection, and aging. Elsevier;
2016. p. 275–294.
[20] Lee J, Go Y, Kang I, et al. Oct-4 controls cell-cycle progression of
embryonic stem cells. Biochem J. 2010;426(2):171–181. doi:10.1042/
BJ20091439. PMID:19968627
[21] Lin T, Chao C, Saito S, et al. p53 induces differentiation of mouse
embryonic stem cells by suppressing Nanog expression. Nat Cell
Biol. 2005;7(2):165–171. doi:10.1038/ncb1211. PMID:15619621
[22] Chambers I, Silva J, Colby D, et al. Nanog safeguards pluripotency
and mediates germline development. Nature. 2007;450(7173):1230–
1234. doi:10.1038/nature06403. PMID:18097409
[23] Silva J, Nichols J, Theunissen TW, et al. Nanog Is the Gateway to the
Pluripotent Ground State. Cell. 2009;138(4):722–737. doi:10.1016/j.
cell.2009.07.039. PMID:19703398
[24] Lahav G, Rosenfeld N, Sigal A, et al. Dynamics of the p53-Mdm2
feedback loop in individual cells. Nat Genet. 2004;36(2):147–150.
doi:10.1038/ng1293. PMID:14730303
[25] Kalmar T, Lim C, Hayward P, et al. Regulated fluctuations in nanog
expression mediate cell fate decisions in embryonic stem cells. Good-
ell MA, ed. PLoS Biol. 2009;7(7):e1000149. doi:10.1371/journal.
pbio.1000149. PMID:19582141
[26] Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization
of real-time quantitative RT-PCR data by geometric averaging of mul-
tiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034.
doi:10.1186/gb-2002-3-7-research0034. PMID:12184808
[27] Asadi MH, Khalifeh K, Mowla SJ. OCT4 spliced variants are highly
expressed in brain cancer tissues and inhibition of OCT4B1 causes
G2/M arrest in brain cancer cells. J Neurooncol. 2016;130(3):455–
463. doi:10.1007/s11060-016-2255-1. PMID:27585657
[28] Qiu C, Ma Y, Wang J, et al. Lin28-mediated post-transcriptional reg-
ulation of Oct4 expression in human embryonic stem cells. Nucleic
Acids Res. 2010;38(4):1240–1248. doi:10.1093/nar/gkp1071.
PMID:19966271
366 M. BARYSHEV ET AL.
